MetaCap

Editas Medicine (EDIT) vs Eikon Therapeutics (EIKN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

Editas Medicine is the larger company by market cap ($422.3 million vs $408.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDIT+51.10%EIKN-48.00%
+108%+26%-57%
Feb 2, 20265 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDIT versus EIKN key metrics
MetricEDITEIKN
Share price$2.75$7.54
Market cap$422.35M$408.40M
1-day change+0.73%+0.40%
5-year return-92.77%—
EPS (TTM)$-0.68$-8.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$4.54$17.40
52-week low$1.66$7.02
Distance from 52-week high-39.39%-56.67%
Average volume2.48M486.76K
Shares outstanding153.58M54.17M
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

EDIT vs EIKN FAQ

Which is bigger, Editas Medicine or Eikon Therapeutics?

Editas Medicine (EDIT) is larger, with a market capitalization of $422.35M compared with $408.40M for Eikon Therapeutics (EIKN).

Are Editas Medicine and Eikon Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons